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Background: Ursodeoxycholic acid (UDCA) is used to treat primary biliary cirrhosis, intrahepatic cholestasis, and other
cholestatic conditions. Although much has been learned about the molecular basis of the disease pathophysiology,
our understanding of the effects of UDCA remains unclear. Possibly underlying its cytoprotective, anti-apoptotic,
anti-oxidative effects, UDCA was reported to regulate the expression of TNFα and other inflammatory cytokines.
However, it is not known if this effect involves also modulation of ADAM family of metalloproteinases, which are
responsible for release of ectodomains of inflammatory cytokines from the cell surface. We hypothesized that UDCA
modulates ADAM17 activity, resulting in amelioration of cholestasis in a murine model of bile duct ligation (BDL).
Methods: The effect of UDCA on ADAM17 activity was studied using the human liver hepatocellular carcinoma cell
line HepG2. Untransfected cells or cells ectopically expressing human ADAM17 were cultured with or without UDCA
and further activated using phorbol-12-myristate-13-acetate (PMA). The expression and release of ADAM17 substrates,
TNFα, TGFα, and c-Met receptor (or its soluble form, sMet) were evaluated using ELISA and quantitative real-time (qRT)
PCR. Immunoblotting analyses were conducted to evaluate expression and activation of ADAM17 as well as the level
of ERK1/2 phosphorylation after UDCA treatment. The regulation of tissue inhibitor of metalloproteinases-1 (TIMP-1) by
UDCA was studied using zymography and qRT-PCR. A mouse model of acute cholestasis was induced by common
BDL technique, during which mice received daily orogastric gavage with either UDCA or vehicle only. Liver injury was
quantified using alkaline phosphatase (ALP), relative liver weight, and confirmed by histological analysis. ADAM17
substrates in sera were assessed using a bead multiplex assay.
Results: UDCA decreases amount of shed TNFα, TGFα, and sMet in cell culture media and the phosphorylation of
ERK1/2. These effects are mediated by the reduction of ADAM17 activity in PMA stimulated cells although the expression
ADAM17 is not affected. UDCA reduced the level of the mature form of ADAM17. Moreover, UDCA regulates the
expression of TIMP-1 and gelatinases activity in PMA stimulated cells. A BDL-induced acute cholangitis model was
characterized by increased relative liver weight, serum levels of ALP, sMet, and loss of intracellular glycogen. UDCA
administration significantly decreased ALP and sMet levels, and reduced relative liver weight. Furthermore, hepatocytes
of UDCA-treated animals retained their metabolic activity as evidenced by the amount of glycogen storage.
Conclusions: The beneficial effect of UDCA appears to be mediated in part by the inhibition of ADAM17 activation
and, thus, the release of TNFα, a strong pro-inflammatory factor. The release of other ADAM17 substrates, TGFα and
sMet, are also regulated this way, pointing to a general impact on the release of ADAM17 substrates, which are pivotal
for liver regeneration and function. In parallel, UDCA upregulates TIMP-1 that in turn inhibits matrix metalloproteinases,
which destroy the hepatic ECM in diseased liver. This control of extracellular matrix turnover represents an additional
beneficial path of UDCA treatment.
Keywords: Ursodeoxycholic acid, ADAM17, Shedding, Cholestasis, Liver* Correspondence: radislav.sedlacek@img.cas.cz
†Equal contributors
Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics
of the ASCR, v. v. i., Videnska 1083, Prague CZ142 20, Czech Republic
© 2013 Buryova et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Buryova et al. BMC Gastroenterology 2013, 13:155 Page 2 of 12
http://www.biomedcentral.com/1471-230X/13/155Background
Ursodeoxycholic acid (UDCA, 3α,7β-dihydroxy-5 β-
cholanic acid) is an approved drug for the treatment
of primary biliary cirrhosis and is also used to treat
several other cholestatic conditions. It has also been
reported to have beneficial effects for liver transplantation
and some diseases not related to liver (for review see [1]).
All data obtained so far suggest at least four mechanisms
of action of UDCA in cholangiopathies: 1) an increased
solubility of endogenous bile acids; 2) stimulation of
hepatocellular and ductular secretions; 3) cellular pro-
tection against bile acid- and cytokine- induced injury;
and 4) anti-inflammatory effects.
Specific effects of UDCA involve regulating the expres-
sion of basolateral bile salt transporters Mrp3 and Mrp4
[2] and the activity of the Cl-/HCO3 anion exchanger AE2
[3]. UDCA also protects cells against apoptosis [4] and
counteracts the mitochondrial permeability transition
induced by hydrophobic bile acids [5], and thus also the
activation of caspases [6], death receptors, and apoptosis
induced by endoplasmic reticulum stress [7]. At the mo-
lecular level, these multiple mechanisms of UDCA action
include direct scavenging of reactive oxygen species (ROS)
[8], increased transcription of antioxidant defense genes [9],
stabilization of the plasma membrane against cytolysis [10]
and reduction of p53 half-life by promotion of its ubi-
quitination and proteasomal degradation [11]. Another
proposed mechanism implies beneficial anti-inflammatory
effects, as UDCA treatment prevents hepatocytes from
necrosis [12], thus reducing the local inflammatory re-
sponse. This observation was confirmed in rats with
bile duct ligation where liver injury is associated with
leucocyte-dependent inflammation mediated by the release
of pro-inflammatory cytokines [13].
The activity of metalloproteinases of the ADAM family is
responsible for release (known as shedding) of membrane-
associated cytokines, growth factors and their receptors,
and adhesion molecules. This shedding process determines
bio(un)availability of the factors and associated signal-
ing during liver injury [14]. For instance, ADAM17 is
responsible for shedding of several dozen cell-surface
molecules, including the ligands of the epidermal
growth factor receptor (EGFR), heparin-binding epidermal
growth factor (HB-EGF), TNFα and its receptors (TNFR)
(for review see [15]). Previous studies have shown that
pharmacologic inhibition of ADAM17 abrogates inflam-
matory responses and has therapeutic potential in a
variety of pathological conditions [16,17]. Interestingly,
administration of marimastat, a broad spectrum inhibitor
of matrix metalloproteinases (MMPs) and ADAM17,
resulted in decreased fibrogenesis during repeated
hepatotoxin-induced liver injury, acting presumably via
the TNF-signaling pathway [18]. Analysis of mice deficient
for TIMP-3, the endogenous inhibitor of ADAM17 [19],revealed elevated levels of TNFα and development of
severe inflammation of the liver, presumably due to an
increase in TNFα converting enzyme activity, i.e. the
activity of ADAM17 [20].
Based on the fact that ADAM17 is a master regulator
of bioavailability of cell-surface bound factors such as TNFα
and TGFα, and the UDCA treatment modulates the levels
of TNFα and other proinflammatory factors [21,22], we in-
vestigated whether UDCA-dependent alteration of TNFα,
TGFα, and sMet levels is controlled via affecting ADAM17
proteolytic activity.
Methods
cDNA constructs and cloning
The human cDNA clone of full-length ADAM17 in
the pCMV6-XL4 vector was obtained from OriGene
(SC316426; OriGene Technologies, Rockville, MD). For
the ectopic expression of untagged versions of ADAM17,
cDNA was PCR-amplified from original plasmids and
subcloned into the multiple cloning site 1 (MSC1) of
the pVitro2-blasti plasmid (InvivoGen, San Diego, CA).
The TdTomato and EGFP coding sequences were then
amplified from plasmids (pEGFP; Clontech, Palo Alto, CA
and pRSET-B-tdTomato; kindly provided by Roger Tsien,
UC San Diego, USA) and subcloned into MSC2 of either
pVitro-ADAM17 or pVitro-ADAM10 vector to generate
pVitro-ADAM17-TdTomato construct encoding ADAM17
and reporter proteins under the control of a composite fer-
ritin promoter. All plasmids were verified by sequencing.
Cell culture experiments
The immortalized human liver hepatocellular carcinoma
cell line HepG2 and the human hepatic stellate cell line
LX2 (a kind gift of Scott Friedman, Mount Sinai, NY)
were grown in Dulbecco's Modified Eagle's Medium
(DMEM; Sigma Aldrich, St. Louis, USA) medium, sup-
plemented with 10% heat-inactivated fetal bovine serum
and 1% penicillin/streptomycin (both PAA Laboratories,
Colbe, Germany). Cells were cultured at 37°C in 5% CO2
and routinely passaged every third day. To obtain sub-
confluent cultures (~80% confluence) for further experi-
ments, cells were seeded at 20 × 103 cells/cm2 in 6-well
culture plates (Costar, Cambridge, MA). Cells were either
left untreated or pretreated with 200 μmol/l UDCA
(Sigma Aldrich, St. Louis, USA) alone or with 10 nmol/l
metalloproteinase inhibitor TAPI-2 (EMD-Millipore,
Billerica, USA) for 2 hours. Cells were then stimulated
with 10 nM PMA (Sigma- Aldrich, St. Louis, USA) for
an additional 24 hours.
Transient transfections of HepG2 and LX2 cells were
carried out in serum free media using X-tremeGENE HP
(Roche, Mannheim, Germany) according to the manufac-
turer’s instructions with 2 μg plasmid and a 1:3 (w/v) ratio
of DNA to transfection reagent. Cells were incubated with
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above after an additional 24 h in media supplemented with
10% heat-inactivated fetal bovine serum and 1% penicillin/
streptomycin. Conditioned media were collected and cen-
trifuged at 12 000 × g for 15 minutes at 4°C. Supernatants
were analyzed for TGFα and TNFα using colorimetric
ELISA assays (R&D, Minneapolis, USA) and an EnVision
Multilabel Reader (PerkinElmer, Waltham, USA). Quanti-
tative cell fractionation of non-treated and UDCA-treated
HepG2 cells was performed as before [23].
Quantitative reverse-transcriptase polymerase chain
reaction (qRT-PCR)
Total RNA was isolated from snap-frozen liver samples or
cell cultures using TriReagent (Sigma-Aldrich, St. Louis,
USA) according to the manufacturer’s instructions. RNA
concentration was determined using a Nanodrop ND-1000
(Thermo Scientific Wilmington, USA). Unique primers
were designed for ~100 bp segments of target gene
transcripts using QuantPrime online software; Table 1).
qRT-PCR was carried out directly from isolated RNA using
Kapa SYBR Fast One-Step qRT-PCR Kit (Kapa Biosystems,
Boston, USA) on a LightCycler 480 (Roche, Mannheim,
Germany). Triplicate reactions were performed with the
following conditions: 95°C for 3 min, followed by 40 cycles
of 95°C for 30 sec, 60°C for 30 sec, and 72°C for 30 sec.
The standard curve method was used to determine relative
mRNA abundance. The relative mRNA levels were cal-
culated by comparative Ct method as before [24] using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
as the control and expressed as fold change of control
sample (arbitrarily set to 1).
Immunoblotting and zymography
Protein samples were obtained ether from cell fractions
(see above) or total protein was isolated from cell cul-
tures using TriReagent (Sigma-Aldrich, St. Louis, USA).
Protein precipitates were dissolved in 1% sodium dode-
cyl sulfate (SDS) and stored at −80°C. Protein concentra-
tions were determined using the BCA Protein Assay Kit
(Thermo Scientific Pierce, Wilmington, USA). ProteinsTable 1 Primer sequences for RT-PCR








GAPDH AATCCCATCACCATCTTCCA TGGACTCCACGACGTACTCAwere separated on 10% SDS gels (25 μg per lane) and
transferred to a nitrocellulose membrane (Whatman,
Maidstone, UK). After blocking with 5% non-fat milk in
Tris-Buffered Saline with 0.1% Tween-20 (TBST), immuno-
blots were probed with the following primary antibodies:
anti-ADAM17 (1:1000; R&D, Minneapolis, USA), anti-
ERK1/2 and anti-phospho-ERK1/2, anti-c-met, anti-c-Src
(all 1:1000; Cell Signaling Technology, Boston, USA), anti-
TGFα and anti-TNFα (both 1:1000; R&D, Minneapolis,
USA), anti-GAPDH (1:50000; Sigma-Aldrich, St. Louis,
USA). Secondary antibodies, rabbit anti-goat and goat
anti-rabbit (both 1:10000; Sigma-Aldrich, St. Louis,
USA), were peroxidase-conjugated. Signals were detected
using ECL plus Western Blotting Detection System (Cell
Signaling Technology, Boston, USA) and recorded with
a Luminescent Image Analyzer (LAS-3000, Fujifilm Life
Science, Düsseldorf, Germany). Densitometry of blots
was performed using AIDA Image Analyser Software
version 2.2 (Raytest, Straubenhardt, Germany).
The activity of gelatinases was assayed using zymography
under nonreducing conditions, as described previously
[24,25]. Briefly, conditioned media were precleared by
centrifugation (5 min, 12000 × g) and protein concentration
was measured by BCA Assay Kit (Thermo Scientific Pierce,
Wilmington, USA). Samples were mixed with SDS sample
buffer (2.0% SDS, 25% glycerol, 0.1% Bromophenol blue
and 60 mM Tris–HCl, pH 6.8) and equal amounts of pro-
tein were separated on 8% polyacrylamide gels containing
1 mg/ml gelatine. Gels were washed, incubated for 24 hours
in Tris–HCl buffer (50 mmol/l Tris–HCl, 10 mmol/l CaCl2,
20 ìmol/l ZnCl2, pH 8.0) at 37°C and subsequently stained
with Coomassie Blue R-250 (Sigma-Aldrich, St. Louis,
USA; 0.125% Coomassie blue R-250, 50% methanol, 10%
acetic acid). Regions representing the gelatinase activity of
MMP2 and MMP9 were quantified using AIDA Image
Analyser Software (Raytest, Straubenhardt, Germany).
Animal model of BDL-induced acute cholestasis
All animal studies were performed in accordance with
European directive 86/609/EEC and were approved by the
Czech Central Commission for Animal Welfare. Animals
were housed in individually ventilated cages under standard
pathogen-free conditions, had ad libitum access to regular
chow (Rod18-A10; LASvendi, Soest, Germany) and chlori-
nated drinking water, and were kept under a 12-hour-dark/
12-hour-light cycle. 10-week-old male C57BL/6NCrl mice
(Charles Rivers Laboratories, Wilmington, MA) were
randomly assigned to four groups: 1) sham followed by
administration of vehicle only; 2) sham followed by
UDCA administration; 3) BDL followed by administration
of vehicle only and 4) BDL followed by UDCA adminis-
tration. Sham surgery and BDL was performed as de-
scribed previously [26]. In brief, animals were anesthetized
with ketamine (80 mg/kg) and xylazine (10 mg/kg). The
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inal incision, double-ligated using 4-0 silk, and sectioned
between the ligatures. Sham-operated mice had their com-
mon bile duct exposed and manipulated but not ligated.
Two days after BDL, mice received either 100 mg/kg
UDCA (Sigma-Aldrich, St. Louis, USA) in 0.1 ml of 2.5%
sodium bicarbonate (pH 7.4) vehicle daily via orogastric
gavage or vehicle alone. These treatments were continued
until study completion. Ten days after BDL, mice were
anesthetized, blood was obtained by retro-orbital bleed,
and animals were sacrificed to evaluate liver damage and
related parameters.
Sera were analyzed for alkaline phosphatase (ALP) using a
commercial kit (Roche Diagnostics, Prague, Czech Republic).
TNFα was assayed with multiplex Bio-Plex mouse array
(Bio-Rad Laboratories, Prague, Czech Republic) using the
Bio-Plex 200 System (Bio-Rad Laboratories, Prague, Czech
Republic). Serum level of mouse sMet was assayed by
ELISA using a kit from R&D Systems (R&D Systems,
Minneapolis, USA).
Histology
Liver lobes were fixed in 4% neutral buffered formaldehyde
for 24 h at 4°C and processed in an automated tissue
processor (Leica Microsystems, Leitz, Germany). To
visualize glycogen deposits, tissue sections of 3 μm in
thickness were stained with periodic acid of Schiff
(PAS) kit (Sigma-Aldrich, St. Louis, USA) according to
manufacturer’s instructions. Analysis of the stained slides
was performed using a Zeiss Axio Imager microscope
(Zeiss Czech Republic, Prague, Czech Republic) equipped
with polarization filter and Axiocam ERc5s digital camera.
Representative images were captured at 40× magnification
and processed consecutively using the GIMP graphic
editor version 2.8 (Free Software Foundation, Boston,
Massachusetts, USA).
Semiquantitative scoring of PAS staining was made by
counting the proportion of PAS-positive and PAS-negative
cells. More than five randomly chosen optical fields
were evaluated, each with >80 cell per field. Staining
was quantitated by blinded scoring on a scale of 0–3+ with:
0, PAS reaction negative; 1+, PAS reaction diffuse and
barely detectable or focal of moderate intensity; 2+, PAS
reaction diffuse, detectable or strong focal reaction but
encompassing less than 50% of the cell cut surface; 3+, PAS
reaction diffuse, moderate to strong or strong focal reaction
encompassing more than 50% of the cell cut surface.
Statistical analysis
Statistical analyses were performed with GraphPad Prism
software version 5.04 (GraphPad Software, San Diego
California, USA). Results from independent experiments
were analyzed with two-tailed one-way ANOVA followed
by Student-Newman-Keuls post-hoc test. Data are presentedas mean values; error bars in figures represent SEM; n values
and statistical significance are specified in figure legends.
Results
UDCA treatment results in reduction of TNFα, TGFα, and
c-Met shedding
To study the effects of UDCA on shedding under condi-
tions reminiscent of the activated state of cells in diseased
liver, human hepatoma HepG2 cells were stimulated with
phorbol-12-myristate-13-acetate (PMA) that is known to
stimulate shedding of TGFα family members [27].
HepG2 cells were pretreated either with UDCA or
vehicle only and following 24 hours of activation, con-
ditioned media were analyzed by ELISA for levels of
shed TNFα, TGFα, and sMet. Experiments revealed
that PMA massively increased shedding of all three
substrates (Figure 1A-C) from the cell surface, and this
effect was already visible after 2 and 4 hours of PMA
stimulation (Additional file 1: Figure S1). However, when
the cells were treated with UDCA prior to stimulation,
this response was significantly reduced, although UDCA
alone had no effect on shedding (Figure 1A-C). While this
inhibitory effect was already apparent on released cytokines
levels from 2 (TNFα) and 4 (sMet) hours of ongoing PMA
stimulation (Additional file 1: Figure S1), only prolonged
incubation (24 hours; Figure 1A-C) resulted in significant
differences in released levels of all measured substrates. In-
creased expression of carbonic anhydrase (CA) and indu-
cible nitric oxide synthase (iNOS) in UDCA-treated HepG2
cells indicated UDCA-dependent activation of farnesoid nu-
clear receptor [28], confirming the proper distribution and
mode of action of UDCA (Additional file 2: Figure S2).
To test whether this PMA-mediated shedding can be
attributed to proteolytic activity of ADAM17, we used
TAPI-2, a specific ADAM17 inhibitor [29]. Pre-treatment
of HepG2 cells with TAPI-2 led to significant reduction of
release of TNFα, TGFα, and sMet into cell media. Regard-
ing TNFα levels (Figure 1A), the inhibitory effect of TAPI-2
was comparable to that of UDCA (Figure 1A-C) suggesting
that UDCA is involved in downregulation of ADAM17
activity, the major TNFα sheddase.
Since PMA has been previously shown to upregulate
the expression of many cytokines and proteins [30], we
tested its effect on TNFα, TGFα, and c-Met. qRT-PCR
analysis of PMA-treated HepG2 cells showed an increase
of the mRNA levels of all factors (Figure 1D-F). Sur-
prisingly, pre-treatment of these cells with UDCA re-
sulted in even higher relative expression of TNFα and
c-Met (Figure 1D,F). The significant increase in TNFα
expression was accompanied by a significant decrease
in TNFα release (Figure 1A) suggesting thus that the
UDCA treatment indeed employs modulation of shed-
ding activities. Only the TGFα mRNA remained, upon
combined treatment with UDCA and PMA, at a level
Figure 1 UDCA reduces shedding of TNFα, TGFα, and c-Met. HepG2 cells were either left untreated (control), or pretreated with 200 μmol/l
UDCA (UDCA), or with 10 nmol/l metalloproteinase inhibitor TAPI-2 (TAPI) for 2 hours. Cells were then either stimulated with 10 nmol/l PMA (PMA) for
an additional 24 hours or left non-stimulated. (A-C) Levels of human TNFα (A), TGFα (B), and sMet (C) in conditioned media were measured by ELISA.
(D-F) In parallel, the relative expression levels of TNFα (D), TGFα (E) and c-Met (F) at the mRNA level were followed by qRT-PCR. Expression of genes of
interest was normalized to GAPDH and expressed as fold change of control sample (for details see Materials and Methods section). Mean values ± SEM
are shown (A-C, n = 3; D-F, n = 5). *p < 0.05; **p < 0.01; ***p < 0.001.
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tive cell fractionation of non-treated and UDCA-treated
HepG2 cells followed by immunoblotting analysis revealed
comparable distribution of TNFα, TGFα, and sMet in both
samples, thereby excluding possible UDCA interference
with the transport of shed substrates to the cell membrane
or their internalization (Additional file 3: Figure S3).
To follow the functional impact of UDCA on ADAM17-
mediated signaling, we monitored the activation status of
mitogen-activated protein kinase 1 and 2 (ERK1/2), the
downstream signal of TGFα binding to the EGF receptor[31]. As shown in (Figure 2A,B), immunoblotting analysis
using anti-phospho-ERK1/2 antibodies revealed that
treatment with UDCA alone had no effect on ERK1/2 ac-
tivation. However, stimulation of HepG2 cells with PMA
resulted in robust increase in ERK1/2 phosphorylation,
which was significantly reduced by pre-treatment with
UDCA (Figure 2).
UDCA interferes with ADAM17 maturation
As UDCA significantly decreased the level of soluble TNFα,









































Figure 2 UDCA treatment decreases ERK1/2 activity. HepG2 cells
were either left untreated (control) or pretreated with 200 μmol/l
UDCA (UDCA) or with 10 nmol/l metalloproteinase inhibitor TAPI-2
(TAPI) for 2 hours. Cells were then either stimulated with 10 nmol/l
PMA (PMA) for an additional 24 hours or left non-stimulated. (A) Cell
lysates from treated and control cells were analyzed by immunoblotting
with anti-ERK1/2, and anti-phospho-ERK1/2 antibodies. Equal amounts of
proteins were loaded in each lane; representative Western blots from
three independent experiments are shown. (B) Signal intensities of
phospho-ERK1/2 bands, which were densitometrically determined in
three independent experiments (including the one shown), were
normalized to ERK1/2 and compared to values obtained for control cells




































































Figure 3 UDCA interferes with ADAM17 maturation. HepG2 cells
were either left untreated (control) or pretreated with 200 μmol/l UDCA
(UDCA) or with 10 nmol/l metalloproteinase inhibitor TAPI-2 (TAPI) for
2 hours. Cells were then either stimulated with 10 nmol/l PMA (PMA) for
an additional 24 hours or left non-stimulated. (A) Cell lysates from treated
and control cells were analyzed by immunoblotting with anti-ADAM17
antibodies. Equal amounts of proteins were loaded in each lane;
representative Western blots from three independent experiments are
shown. (B) Signal intensities of mature ADAM17 bands (85 kDa), which
were densitometrically determined in three independent experiments
(including the one shown), were normalized to immature ADAM17 form
(130 kDa). Mean values ± SEM are shown (n = 3). *p < 0.05; **p < 0.01.
(C) mRNA was isolated from HepG2 cells as described in the text. The
relative expression levels of ADAM17 were followed by qRT-PCR.
Expression was normalized to GAPDH and expressed as fold change of
control sample. Mean values ± SEM are shown (n = 3). *p < 0.05.
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ADAM17, i.e. whether the formation of the mature form
of ADAM17 is affected. The exposure of HepG2 cells to
PMA resulted in a pronounced formation of the mature
form of ADAM17 whereas the presence of UDCA alone
had no effect (Figure 3A,B). However, pre-treatment of
cells with UDCA prior to PMA stimulation resulted in a
significant decrease in the formation of the mature form
of ADAM17 (Figure 3B). Similarly to TNFα expression
(Figure 1A), RT-PCR analysis showed that ADAM17
mRNA levels rose after combined PMA and UDCA
treatment, but this increase did not lead to a consequent
elevation in ADAM17 shedding (Figure 3C).
To address the question of how the UDCA inhibitory
effect on ADAM17 applies to non-hepatocyte cell types
in the liver, human hepatic stellate cells LX2 were pre-
treated either with UDCA or vehicle only and stimulated
for a following 24 hours with PMA. Conditioned media
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sMet as before. Similar to data obtained with HepG2
cells, these experiments revealed that PMA significantly
increased shedding of both substrates (Figure 4A-B) from
the cell surface. Treatment with UDCA prior to stimulation
resulted in reduction of LX2 cells response (Figure 4A-B)
although the effect was not as prominent as for HepG2
cells (compare Figure 1A-C and Figure 4A-B). As UDCA
exhibited similar impact on LX2 cells, it is likely that the
inhibitory effect of UDCA on ADAM17-mediated release
of membrane-bound substrates in PMA-stimulated cells is
a general mechanism.
As UDCA treatment in patients with cholestasis and
cirrhosis are beneficial to hepatic functions, and this may




































Figure 4 UDCA reduces TNFα and c-Met shedding in LX2 cells.
LX2 cells were either left untreated (control) or pretreated with
200 μmol/l UDCA (UDCA) or with 10 nmol/l metalloproteinase
inhibitor TAPI-2 (TAPI) for 2 hours. Cells were then either stimulated
with 10 nmol/l PMA for an additional 24 hours or left non-stimulated.
(A-B) Levels of human TNFα (A) and sMet (B) in conditioned media
were measured by ELISA. Mean values ± SEM are shown
(n = 3). *p < 0.05.[33-35], we also analyzed whether UDCA influences
MMPs. Interestingly, qRT-PCR analysis revealed that
mRNA levels of TIMP-1 and -3 increased in cells treated
with both PMA and UDCA (Figure 5A,B). However, the
UDCA treatment alone had no significant effect on their
expression. Since TIMP-1 acts as an endogenous inhibitor
of matrix metalloproteinase 9 (MMP9) [36], we next ex-
amined its proteolytic activity using zymography. Analysis
of conditioned media revealed two clear bands (Figure 5C)
corresponding to pro- and active MMP9 forms. The inten-
sities of the 92 kDa band, indicating the pro-form, and the
84 kDa band, indicating the processed/active form, were
both clearly elevated upon PMA stimulation when com-
pared to the basal level detected in non-stimulated cells
(control). Although the expression of MMP9 appeared even
higher after combined treatment with UDCA and PMA,
the conversion to active MMP9 84 kDa-form was reduced
in comparison to PMA stimulation (Figure 5C,D).
UDCA administration reduces serum level of ADAM17
substrates and preserves functional activity of
hepatocytes in BDL mice
To further explore the effects of UDCA on ADAM17-
mediated shedding, C57BL/6NCrl mice were subjected
to common BDL and subsequently treated with UDCA via
orogastric gavage for 6 days (Figure 6A).
The body weights of 8 day BDL and SHAM animals
treated with UDCA or vehicle were significantly lower
than the control group of untreated animals. However,
consistent with previously published results, UDCA had a
beneficial effect on the course of acute cholestasis [37-39].
UDCA administration attenuated hepatocellular damage as
documented by significantly reduced ALP levels in serum
(Figure 6B), decreased relative liver weight, the reliable indi-
cator of hepatic injury (Figure 6C), and by histochemical
analysis (Figure 7A,B).
Under these conditions we evaluated serum levels of
two known ADAM17 substrates, TNFα and sMET, which
are linked to development of liver injury (Figure 6D,E).
ELISA analyses showed that the level of sMet was signifi-
cantly reduced in BDL animals treated with UDCA com-
pared to untreated BDL group (Figure 6E). Similar effects,
however less pronounced, were observed upon adminis-
tration of UDCA in sham-operated groups (Figure 6E).
Such reduction of sMet levels is not only fully consistent
with moderate liver injury, but also likely reflects the
lower activity of ADAM17 in livers of UDCA-treated ani-
mals. Although not significant, a similar effect or tendency
was also seen in TNFα levels in BDL animals treated with
UDCA (Figure 6D). Generally, TNFα levels were higher in
all experimental groups, including the sham controls,
compared to control animals (Additional file 4: Figure S4).
























































































Figure 5 UDCA-treatment upregulates the expression of TIMP-1 and alters MMP9 activity. HepG2 cells were either left untreated (control)
or pretreated with 200 μmol/l UDCA (UDCA) for 2 hours. Cells were then either stimulated with 10 nmol/l PMA (PMA) for an additional 24 hours
or left non-stimulated. (A,B) The relative expression levels of TIMP-1 and TIMP-3 were assayed by qRT-PCR. Expression was normalized to GAPDH
and expressed as fold change of control sample. Mean values ± SEM are shown (n = 3). ***p < 0.001. (C) Conditioned media from treated and
control cells were analyzed for the expression and activity of MMP9 and MMP2 using zymography. Equal amounts of proteins were loaded in
each lane. (D) Band intensities of MMP9 proform (pro-MMP9) were densitometrically determined in three independent experiments
(including the one shown) and compared to the active MMP9 form (92 kDa); the diagram shows pro-MMP9/MMP9 ratio. Mean values ± SEM are
shown (n = 3). *p < 0.05.
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these findings. Period acid Schiff (PAS) staining revealed
that the hepatocytes of UDCA-treated BDL animals
retained substantially greater amounts of intracellular
glycogen than did those of the untreated BDL group
(Figure 7A,B). In fact, the staining intensity of preserved
intracellular glycogen granules after UDCA administration
was indistinguishable from those observed in sham-
operated animals (Figure 7A,B), suggesting comparable
metabolic activity of the hepatocytes.
Taken together, these findings indicate that the inhibition
of ADAM17 in response to UDCA treatment can provide
an additional mechanistic explanation for the hepatoprotec-
tive effects of UDCA in acute cholestasis.
Discussion
UDCA is currently only approved by the FDA to treat
primary biliary cirrhosis (PBC), however, it exhibits no
benefit in patients with primary sclerosing cholangitis
(PSC) [40,41]. UDCA-treatment of PBC patients resultsin a decrease of serum markers of hepatic damage and
its beneficial effect is believed to be based on its cytoprotec-
tive, anti-apoptotic, anti-oxidative, and immunomodulating
functions [22]. However, the mechanism of the UDCA
impact is still fragmentary.
Although regulation of TNFα levels after UDCA treat-
ment has been documented in patients as well as in rodent
models [21,22], there are no reports about the mechanism
how UDCA influences its bioavailability. Unlike other
proinflammatory factors such as IL-1 and IL-6, TNFα
must be released from the cell-surface via a process
termed ectodomain shedding [42,43]. This shedding con-
trols also bioavailability of factors belonging to the TGFα
family and, thus, this process is of pivotal importance for
liver pathophysiology as many signaling mediators such as
TNFα, TGFα, and others [21,22] need to be released from
the cell membrane to be active as ligands [15,27,42].
In this work we focused on TNFα, TGFα, and
sMet, the factors that are released from the cell-surface
due to the shedding activity of the ADAM family of
Figure 6 UDCA treatment results in reduced sMet serum levels and relative liver weight in a mouse model of acute cholestasis.
(A) Schematic representation of a model of BDL-induced acute cholestasis. Acute cholestasis was induced in C57BL/6NCrl mice by common bile
duct ligation (for details see Materials and Methods). Serum and the whole liver were collected from sham-operated animals treated with vehicle
only (SHAM), sham-operated animals treated with UDCA (SHAM UDCA), animals with ligated bile ducts treated with vehicle only (BDL), and
animals with ligated bile ducts treated with UDCA (BDL UDCA). Serum levels of ALP (B), TNFα (D) and sMet (E) were assessed as described in the
text. (C) Relative liver weight was calculated as the ratio of liver weight to body weight (100%). Mean values ± SEM are shown (n = 4).
*p < 0.05; ***p < 0.001.
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http://www.biomedcentral.com/1471-230X/13/155metalloproteinases. The data shown here clearly show
that UDCA decreases the levels of ADAM17 sub-
strates and that this reduction is due to an inhibition
of ADAM17 maturation.
Inflammation inducers such as bacterial lipopolysachar-
ides, ceramide, or PMA induce shedding by activation of
metalloproteinase 7 (MMP7) and ADAM17 [44,45].
Although the exact biological significance of ligand orreceptor shedding is unclear in most liver pathologies,
it is widely accepted that the level of TNFα is hallmark
of disease progression and that UDCA treatment is
beneficial for liver regeneration and the reduction of
inflammation [22]. This is also supported by our findings
that UDCA treatment reduced TNFα shedding. In spite
of the combination of UDCA and PMA increasing the













Figure 7 UDCA treatment preserves PAS-positive collagen
aggregates in the liver with acute cholestasis. (A) Tissue
sections of liver isolated from sham-operated animals treated with
vehicle only (SHAM), sham-operated animals treated with UDCA
(SHAM UDCA), animals with ligated bile ducts treated with vehicle
only (BDL), and animals with ligated bile ducts treated with UDCA
(BDL UDCA) were stained with PAS for glycogen storage in hepatocytes.
Bar, 50 μm. (B) Intensity of PAS reaction was semiquantitatively evaluated
and normalized as described in the text; >80 cells per field from more
than five randomly chosen optical fields of each dissected liver. Mean
values ± SEM are shown (n = 4). ***p < 0.001.
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findings, experiments with the ADAM17 specific inhibitor
TAPI-2 supported the conclusion that UDCA blocks
activity of ADAM17 by inhibiting the formation of the
mature form of ADAM17.
TGFα, which is produced in hepatocytes and released
by ADAM17 during liver regeneration, is part of an early
cytokine and growth factor response and one of the es-
sential ligands for EGFR stimulation. The activation of
EGFR promotes cell proliferation and survival, via sig-
naling through the ERK pathway [42]. We found that
levels of TGFα are reduced in cells pre-incubated with
UDCA and stimulated with PMA. As a functional conse-
quence of the lower activity of ADAM17, TGFα release
and EGFR activation were reduced as demonstrated by
lower phosphorylation of ERK.
Hepatocyte growth factor and its receptor c-Met rep-
resent the main proliferative axis in hepatocytes. It has
been proposed that c-Met receptor is shed by ADAM10
[46] and recently it was also reported to be an ADAM17substrate [47]. Shedding of c-Met differs from EGFR or
cytokines release, as it causes inactivation of receptor and
eliminates its signaling [48]. In comparison to TNFα and
TGFα, sMet exhibited the most sensitive change to UDCA
treatment. Also the ectopic expression of ADAM17 with-
out PMA stimulation already increased sMet concentration
in media. Inhibition of ADAM17 and releasing of sMet by
TAPI-2 confirmed previously reported c-Met shedding by
ADAM17 in LX-2 cells [24]. The elevated sensitivity of
c-Met towards PMA and UDCA treatment could be caused
by higher expression of c-Met in hepatocytes, about ten
times more than TNFα and TGFα.
The UDCA-dependent decrease of TNFα serum levels
due to the inhibition of ADAM17 activity, likely has a bene-
ficial effect as TNFα exhibits strong pro-inflammatory ef-
fects. However, inhibition of the release of TGFα and sMet
might have some adverse effect on liver function as these
factors together with their receptors are crucial for liver re-
generation (for review see [49]). Thus, our findings based
on UDCA-mediated inhibition of the shedding activity of
ADAM17 may explain why, for instance, UDCA exhibits
low or no beneficial effect on primary sclerosing cholangitis
and other chronic liver diseases [1,50]: inhibiting the activ-
ity of ADAM17 appears to result in diminished inflamma-
tory reactions but, in parallel, it may exhibit adverse effects
due to inhibition of c-Met and EGFR signaling on liver
regeneration and function.
Conclusions
In the present study we demonstrate that UDCA affects
the activity of ADAM17, which in turn results in decreased
shedding of ADAM cell-surface bound factors such as
TNFα, TGFα, and c-Met. UDCA treatment also increases
the expression of matrix metalloproteinase inhibitor TIMP-
1, thereby preventing MMPs from their deteriorative pro-
teolytic activity in the liver. Altogether, these results identify
ADAM17 as a novel target of UDCA in hepatocytes
and study improve our overall understanding of UDCA
treatment and its beneficial effects.
Additional files
Additional file 1: Figure S1. UDCA reduces shedding of TNFα and
c-Met in PMA-stimulated cells. HepG2 cells were either left untreated
(control), or pretreated with 200 μmol/l UDCA (UDCA) for 2 hours. Cells
were then either stimulated with 10 nmol/l PMA (PMA) for either 2 (A,B)
or 4 (C,D) hours, or left non-stimulated. Levels of human TNFα (A,C) and
sMet (B,D) in conditioned media were measured by ELISA. Mean
values ± SEM are shown (n = 3). *p < 0.05.
Additional file 2: Figure S2. UDCA-treated HepG2 cells exhibit
increased expression of carbonic anhydrase (CA) and inducible nitric
oxide synthase (iNOS). HepG2 cells were either left untreated (control) or
pretreated with 200 μmol/l UDCA (UDCA) for 2 hours. Cells were then
either stimulated with 10 nmol/l PMA (PMA) for an additional 24 hours or
left non-stimulated. Relative expression levels of carbonic anhydrase
(CA; A) and inducible nitric oxide synthase (iNOS; B) were assayed by
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http://www.biomedcentral.com/1471-230X/13/155qRT-PCR. Expression of both genes was normalized to GAPDH and
expressed as fold change of control sample (for details see Materials and
Methods section). Mean values ± SEM are shown (n = 3). **p < 0.01.
Additional file 3: Figure S3. UDCA treatment does not affect
distribution of TNFα, TGFα, and c-Met between membrane and
cytoplasmic compartments. Tolal lysate (Lysate) and membrane
subfractions of non-treated (control) and UDCA-treated (UDCA)
HepG2 cells normalized for equal protein contents, were
immunoblotted using antibodies to TNFα, TGFα, and c-Met.
GAPDH and c-Src were used as loading controls.
Additional file 4: Figure S4. Sham animals have elevated inflammation
markers. Acute cholestasis was induced in C57BL/6NCrl mice by common
bile duct ligation. Serum and the whole liver were collected from
sham-operated and from animals without any surgery. Serum levels of
ALP (A), sMet (C) and TNFα (D) were assessed as described in materials
and methods. (B) Relative liver weight was calculated as the ratio of liver
weight to body weight (100%). Mean values ± SEM are shown (n = 4).
**p < 0.01.
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